Knock it off: Biosim­i­lars are not a 'knock­of­f' drug

I like nice Nikes. Some can get pricey. Would I’d nev­er wear a knock­off? No.


Let’s start at square one by ask­ing: why don’t we just call biosim­i­lars gener­ics? Or bio-gener­ics?

The pub­lic doesn’t know what a biosim­i­lar is, but gener­ics are stan­dard fare: cheap­er ver­sions pricey drugs that work. Biosim­i­lars promise to bring the cost of health­care down and ac­cess to cru­cial med­i­cines up, just like gener­ics. And now, the FDA just gave a vig­or­ous en­dorse­ment to two fran­chise-bust­ing biosim­i­lars on all in­di­ca­tions as the orig­i­nal drug.  These med­i­cines look every bit as good as brand­ed Hu­mi­ra and En­brel.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.